This page shows the latest Dinutuximab beta news and features for those working in and with pharma, biotech and healthcare.
field.”. The UK-based group has also recently received another EU approval for the rare cancer drug dinutuximab beta as a treatment for high-risk neuroblastoma patients over the age of
CHMP recommendations also include Trumenba, Dinutuximab beta and Refixia. MSD and Bristol-Myers Squibb (BMS) both picked up positive opinions for their PD-1 inhibitors from the EMA's advisory committee ... Apeiron Biologics also got the go-ahead for
More from news
Approximately 0 fully matching, plus 2 partially matching documents found.
No results were found
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...